Scientific jobs

Update on Scientific Specialist - Inspections

We wish to inform those interested that the selection procedure for the Senior Scientific Specialist - Inspections (EMA/AD/11188) has been withdrawn in view of the ongoing legislative process.

Scientific jobs

As a scientific officer at EMA, you will typically be responsible for activities related to human or veterinary medicines in areas such as procedure and scientific management, scientific committee support, pharmacovigilance, and inspections and quality.

You will have obtained a degree in a science field and have proven work experience in the field of medicines regulation from the pharmaceutical industry, a national competent authority or academia. You will have knowledge and understanding of scientific aspects of medicines development, clinical trials methodology, signal detection and pharmacoepidemiology. You will be a curious, solution-driven team player who can communicate verbally and in writing with various audiences.

Title Deadline for application Type of position
SNE/Veterinary Pharmacovigilance Specialist
SNE/Veterinary Pharmacovigilance Specialist 11 January 2026 23:59 CET Seconded National Expert
11 January 2026 23:59 CET Seconded National Expert
SNE/Scientific Specialist in Regulatory science and academia Workstream (TRS-ACD) 04 January 2026 23:59 CET Seconded National Expert
SNE/Biostatistician Specialist (evidence generation)
SNE/Biostatistician Specialist (evidence generation) 09 January 2026 at 23.59 CET Seconded National Expert
09 January 2026 at 23.59 CET Seconded National Expert

What is it like to work in the Human Medicines Division?

Regulatory Science to 2025 - Shaping the future

 

As science and technology advance and bring potential new treatments and diagnostic tools, regulatory science must advance in tandem so that these can be correctly, rigorously and efficiently assessed. Examples of the transformational research that is having a significant impact on the regulatory science agenda include cell-based therapies, genomics-based diagnostics, drug-device combinations, novel clinical trial design, predictive toxicology, real-world evidence, and ‘big data’ and artificial intelligence.